Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C.

Alimentary pharmacology & therapeutics - 1 May 2012

Brennan B J, Morcos P N, Wang K, Blotner S D, Morrison R, Hagedorn C H, Marbury T C, Sulkowski M, Grippo J F

Abstract excerpt

BACKGROUND: Amongst Caucasian, Hispanic and African Americans with genotype 1 hepatitis C virus (HCV), there is a wide variation in response to treatment with peginterferon alfa-2a (PEG-IFN alfa-2a) and ribavirin. AIM: To evaluate the pharmacokinetics (PK) of PEG-IFN alfa-2a and ribavirin among these three groups. METHODS: Forty-seven patients with genotype 1 CHC (17 African Americans, 14 Hispanics and 16...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Black or African American

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Hepatitis C, Chronic

Share to Hispanic or Latino

Share to Interferon-alpha

Share to Polyethylene Glycols

Share to Ribavirin

Source

Identifiers

PMID: 22469033
DOI: 10.1111/j.1365-2036.2012.05079.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C.PMID 22469033Read ↗

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.Semantic proximity Read ↗

Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection.Semantic proximity Read ↗

Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection.Semantic proximity Read ↗

Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection.Semantic proximity Read ↗

Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic.Semantic proximity Read ↗

Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1.Semantic proximity Read ↗

Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3.Semantic proximity Read ↗

Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity.Semantic proximity Read ↗

Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in hispanics compared to non-Hispanic whites.Semantic proximity Read ↗

Associations between serum lipids and hepatitis C antiviral treatment efficacy.Semantic proximity Read ↗

Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.Semantic proximity Read ↗

Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.